419 related articles for article (PubMed ID: 24905296)
1. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
3. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
4. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
Gu J; Fan YQ; Han ZH; Fan L; Bian L; Zhang HL; Xu ZJ; Yin ZF; Xie YS; Zhang JF; Wang CQ
Int J Cardiol; 2016 Oct; 220():56-60. PubMed ID: 27372043
[TBL] [Abstract][Full Text] [Related]
5. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
6. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
7. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
[TBL] [Abstract][Full Text] [Related]
8. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).
Deswal A; Richardson P; Bozkurt B; Mann DL
J Card Fail; 2011 Aug; 17(8):634-42. PubMed ID: 21807324
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
10. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
[TBL] [Abstract][Full Text] [Related]
11. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
[TBL] [Abstract][Full Text] [Related]
12. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
13. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
Zile MR; Bourge RC; Redfield MM; Zhou D; Baicu CF; Little WC
JACC Heart Fail; 2014 Apr; 2(2):123-30. PubMed ID: 24720918
[TBL] [Abstract][Full Text] [Related]
15. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
[TBL] [Abstract][Full Text] [Related]
17. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
[TBL] [Abstract][Full Text] [Related]
18. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
[TBL] [Abstract][Full Text] [Related]
20. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.
Upadhya B; Hundley WG; Brubaker PH; Morgan TM; Stewart KP; Kitzman DW
J Am Geriatr Soc; 2017 Nov; 65(11):2374-2382. PubMed ID: 28542926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
